IP Library › Granted Patent US 12,676,238
Granted Patent B2
US 12,676,238 · App. 18/779,585 · Granted Jul 7, 2026

Interactive and analytical system that provides a dynamic tool for therapies to prevent and cure dementia-related diseases

Inventor: John Quillian Walker, II (Mountain City, TN)
Assignee: uMethod Health, Inc.
G16H50/20G16H50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,676,238
App. No.
18/779,585
Filed
Jul 22, 2024
Granted
Jul 7, 2026
Kind
B2
Art Unit
3684
USPC
702/19
Abstract

A computer-implemented method, system, and apparatus for providing interactive and analytical components that provide a comprehensive and dynamic tool for therapies to prevent and cure dementia-related diseases. The invention includes one or more computers that receive and store personal information for people, including personal background information, pre-existing conditions, current medications, genomic data and diagnostic information. The computers also generate synergic data containing compounded probability data specifying an expected adjustment of individual biological mechanisms from particular combinations of therapies. For each person, the computers process personal information and identify a subset of biological mechanisms that are principally affected by dementia-related diseases or the substantial risk of dementia-related diseases. The computers also apply the personal information including the principally-affected biological mechanisms to the therapy data and generate for each person one or more messages communicating a therapy plan containing a combination of therapies and determines how to apply the therapies.

Claims (34)

1 . A method for providing a therapy to a participant to improve cognitive health of the participant, the method comprising:

using a monitoring server for:

receiving participant information including dietary and food intake information of the participant;

receiving therapy plan information, wherein the therapy plan information includes a plurality of individual therapy plans, each individual therapy plan specifying an individual biological mechanism targeted for physiological adjustment, variations found in an effect on the targeted biological mechanism as a function of the participant information, and data quantifying a probability of success of the individual therapy plan;

generating an aggregate therapy plan for improving cognitive impairment within the participant, wherein the aggregate therapy plan targets adjustment of a plurality of biological mechanisms using a combination of the individual therapy plans including dietary changes, wherein the aggregate therapy plan comprises an aggregate probability reflecting a likelihood of achieving all targeted adjustments;

receiving diagnostic and testing data associated with the participant, wherein the diagnostic and testing data is captured after the participant has undergone treatment according to the aggregate therapy plan;

for each individual therapy plan in the aggregate therapy plan:

determining a value corresponding to the individual biological mechanism in the participant based on the received diagnostic and testing data and the participant information including the dietary and food intake information of the participant;

performing a comparison of the value to a recommended range for the value,

based on the comparison, dynamically adjusting the individual therapy plan including the dietary changes plan for the biological mechanism when the value is not within the recommended range;

generating, for the participant, an adjusted aggregate therapy plan based on the individual therapy plan adjustments; and

adjust the therapy plan information to include a medication adjustment based on success of the individual therapy plans of the participant and of other participants;

and

further administering the adjusted aggregate therapy plan including the medication adjustment to the participant.

2 . The method of claim 1 , wherein participant data is provided at a participant device for use by a provider or the participant, the participant device operable to receive provider data from a therapy provider.

3 . The method of claim 2 , wherein the participant device is a mobile device having an imaging device, whereby the participant images food to be consumed with the mobile device.

4 . The method of claim 3 , wherein the dietary and food intake information includes images of food to be consumed before consumption and after consumption.

5 . The method of claim 3 , wherein the monitoring server is operable to determine a characteristic of the imaged food based on color, color intensity, and color variation of the food.

6 . The method of claim 3 , wherein the monitoring server is operable to determine or receive information related to a mass, amount, or caloric intake of the imaged food.

7 . The method of claim 3 , wherein the monitoring server is operable to transmit instructions related to the therapy plan to a participant in response to determining a characteristic of the imaged food.

8 . The method of claim 3 , wherein the monitoring server is operable to:

store in a database one or more images of food and beverages being consumed by the participant; and

compare the one or more images of food and beverages being consumed by the participant to images of known foods and beverages.

9 . The method of claim 3 , wherein in order to generate the aggregate therapy plan the monitoring server is further operable to determine frequency of meals, time of day of consumption, and other data based on the imaged food and beverage.

10 . The method of claim 1 , wherein the monitoring server is operable to determine a freshness of the participant information.

11 . The method of claim 1 , wherein the monitoring server is operable to determine at least one item comprising the participant information is missing, and, in response to determining at least one item is missing, determine a criticality associated with the at least one item.

12 . The method of claim 1 , wherein the monitoring server is operable to receive the participant information from electronic health records.

13 . The method of claim 1 , wherein the monitoring server is operable to determine if the participant is a candidate for a dementia-related disease based on the participant information.

14 . The method of claim 13 , wherein the monitoring server is operable to determine a level of risk for the participant, and determine if the participant is a candidate based on the determined level of risk.

15 . The method of claim 1 , wherein the monitoring server is operable to prioritize ones of the biological mechanisms based on participant information and data associated with a group of participants.

16 . The method of claim 15 , wherein the monitoring server is operable to generate the aggregate therapy plan based on a priority of the biological mechanisms.

17 . The method of claim 1 , wherein the monitoring server is operable to store information regarding a participant's previous compliance with a previous aggregate therapy plan.

18 . The method of claim 1 , wherein the monitoring server is operable to adjust the therapy plan information based on the participant information and other participant information.

19 . The method of claim 1 , wherein the individual therapy plans include at least two therapy options where a second therapy option follows a first therapy option if the values of the biological mechanism are not within the recommended range.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2024
From: WALKER, JOHN QUILLIAN, II
To: UMETHOD HEALTH, INC.
Reel/Frame 068044/0182 →
Continuity (17)
Continuation 17676562 · Feb 21, 2022
Continuation 16665862 · Oct 28, 2019
Continuation In Part 15253807 · Aug 31, 2016
Continuation In Part 15253818 · Aug 31, 2016
Continuation In Part 15243908 · Aug 22, 2016
Continuation In Part 15243917 · Aug 22, 2016
Continuation In Part 15243908 · Aug 22, 2016
Continuation In Part 15243917 · Aug 22, 2016
Continuation In Part 15243908 · Aug 22, 2016
Continuation In Part 15243917 · Aug 22, 2016
Continuation In Part 14788770 · Jun 30, 2015
Continuation 14167943 · Jan 29, 2014
Provisional Application 62212530 · Aug 31, 2015
Provisional Application 62212528 · Aug 31, 2015
Provisional Application 62208606 · Aug 22, 2015
Provisional Application 62208614 · Aug 22, 2015
Related Publication 20240379238A1 · Nov 14, 2024
References Cited (95)
US 4839822A · Dormand et al. · 1989 [cited by applicant]
US 4974254A · Perine et al. · 1990 [cited by applicant]
US 5235510A · Yamada et al. · 1993 [cited by applicant]
US 5245995A · Sullivan et al. · 1993 [cited by applicant]
US 5255187A · Sorenson · 1993 [cited by applicant]
US 5262943A · Thibado et al. · 1993 [cited by applicant]
US 5769074A · Barnhill et al. · 1998 [cited by applicant]
US 5983379A · Warren · 1999 [cited by applicant]
US 5993386A · Ericsson · 1999 [cited by applicant]
US 6024699A · Surwit et al. · 2000 [cited by applicant]
US 6052619A · John · 2000 [cited by applicant]
US 6081786A · Barry et al. · 2000 [cited by applicant]
US 6126596A · Freedman · 2000 [cited by applicant]
US 6165126A · Merzenich et al. · 2000 [cited by applicant]
US 6188988B1 · Barry et al. · 2001 [cited by applicant]
US 6223074B1 · Granger · 2001 [cited by applicant]
US 6282305B1 · Huo et al. · 2001 [cited by applicant]
US 6475161B2 · Teicher et al. · 2002 [cited by applicant]
US 6523009B1 · Wilkins · 2003 [cited by applicant]
US 6853864B2 · Liovitz · 2005 [cited by applicant]
US 6876972B1 · Kameda · 2005 [cited by applicant]
US 7029275B2 · Rubbert et al. · 2006 [cited by applicant]
US 7299192B2 · Luttrell · 2007 [cited by applicant]
US 7321861B1 · Oon · 2008 [cited by applicant]
US 7366572B2 · Heruth et al. · 2008 [cited by applicant]
US 7630750B2 · Liang et al. · 2009 [cited by applicant]
US 7801270B2 · Nord et al. · 2010 [cited by applicant]
US 8321372B1 · Rakshit et al. · 2012 [cited by applicant]
US 8494875B2 · Broselow · 2013 [cited by applicant]
US 8545435B2 · Bui · 2013 [cited by applicant]
US 10276260B2 · Moturu et al. · 2019 [cited by applicant]
US 20020007286A1 · Okamoto · 2002 [cited by applicant]
US 20020038227A1 · Fey et al. · 2002 [cited by applicant]
US 20020086290A1 · Sevigny · 2002 [cited by examiner]
US 20020107707A1 · Naparstek et al. · 2002 [cited by applicant]
US 20020198742A1 · Kameda et al. · 2002 [cited by applicant]
US 20030014284A1 · Jones · 2003 [cited by applicant]
US 20030028399A1 · Davis et al. · 2003 [cited by applicant]
US 20040006495A1 · Dudley · 2004 [cited by applicant]
US 20050021240A1 · Berlin et al. · 2005 [cited by applicant]
US 20050021679A1 · Lightman et al. · 2005 [cited by applicant]
US 20050038371A1 · Reich · 2005 [cited by examiner]
US 20050283054A1 · Reiman · 2005 [cited by examiner]
US 20060167529A1 · Schecter · 2006 [cited by applicant]
US 20070122824A1 · Tucker et al. · 2007 [cited by applicant]
US 20070172844A1 · Lancaster et al. · 2007 [cited by applicant]
US 20080031406A1 · Yan et al. · 2008 [cited by applicant]
US 20080118918A1 · Licinio · 2008 [cited by examiner]
US 20080182220A1 · Chishti et al. · 2008 [cited by applicant]
US 20090012818A1 · Rodgers · 2009 [cited by applicant]
US 20090220429A1 · Johnsen et al. · 2009 [cited by applicant]
US 20090271008A1 · Hyde et al. · 2009 [cited by applicant]
US 20100081971A1 · Allison · 2010 [cited by applicant]
US 20100280531A1 · Kalpin · 2010 [cited by examiner]
US 20110119212A1 · De Bruin et al. · 2011 [cited by applicant]
US 20110159527A1 · Schlossmacher et al. · 2011 [cited by applicant]
US 20110251854A1 · Chung · 2011 [cited by applicant]
US 20120203573A1 · Mayer · 2012 [cited by examiner]
US 20120270190A1 · Kenedy et al. · 2012 [cited by applicant]
US 20140142140A1 · Bird · 2014 [cited by examiner]
US 20140310025A1 · Sayada · 2014 [cited by examiner]
US 20150025917A1 · Stempora · 2015 [cited by applicant]
US 20150213232A1 · Walker, II · 2015 [cited by examiner]
US 20150228062A1 · Joshi et al. · 2015 [cited by applicant]
US 20160012749A1 · Connor · 2016 [cited by applicant]
US 20170333733A1 · Glimelius et al. · 2017 [cited by applicant]
DE 102009018809A1 · 2010 [cited by applicant]
EP 1500025B1 · 2008 [cited by applicant]
GB 2354853A · 2001 [cited by applicant]
WO 2001039089A1 · 2001 [cited by applicant]
WO 2002067177A2 · 2002 [cited by applicant]
WO 03094092A1 · 2003 [cited by applicant]
Erin Allday, “Researchers dig deeper for Alzheimer's cure”, 5 pages, Nov. 19, 2013, http://www.sfgate.com/health/article/Researchers-dig-deeper-for-Alzheimer-s-cure-499453 . . . . [cited by applicant]
David Perlmutter and Kristin Loberg, “Grain Brain, The Surprising Truth About Wheat, Carbs, and Sugar—Your Brain's Silent Killers”, Little, Brown and Company, Sep. 2013, Chapters 7-9; 26 pages. [cited by applicant]
Doraiswamy, P., et al., “The Alzheimer's Action Plan”, St. Martin's Griffin, May 2009, Chapters 6, 7, 8 and 10; pp. 72-138 and 164-177. [cited by applicant]
Tenenbaum, Jay M., et al., “Cancer: A Computational Disease That AI Can Cure”, IAAI Articles, Ai Magazine, Summer 2011, pp. 14-26. [cited by applicant]
Gabhann, F., et al., “Multi-scale Computational Models of Pro-angiogenic Treatments in Peripheral Arterial Disease”, Annals of Biomedical Engineering, vol. 35, No. 6, Jun. 2007, pp. 982-994. [cited by applicant]
Polaschek J., et al., “A Computer Program for Statistically-Based Decision Analysis”, SCAMC, Inc., pp. 795-799. [cited by applicant]
Jansen, J., et al., “Teach-Discover-Treat (TDT): Collaborative computational drug discovery for neglected diseases”, Elsevier, Journal of Molecular Graphics and Modelling, vol. 38, 2012, pp. 360-362. [cited by applicant]
Theendakara, V., et al., “Neuroprotective Sirtuin ratio reversed by ApoE4”, PNAS Early Edition, 2013, pp. 1-6. [cited by applicant]
Small, G., et al., “The Alzheimer's Prevention Program: Keep Your Brain Healthy for the Rest of Your Life”, The Alzheimer's Prevention Program, Dec. 11, 2012, https://www.amazon.com/Alzheimers-Prevention-Program-Brain-H… [cited by applicant]
Jean Carper, “100 Simple Things You Can Do to Prevent Alzheimer's and Age-Related Memory Loss”, 6 pages, https://www.amazon.com/Simple-Things-Prevent-Alzheimers-Age-Related/dp/B005UVQBL6, Feb. 26, 2014. [cited by applicant]
USPTO; Final Office Action for U.S. Appl. No. 15/253,818 dated Jul. 31, 2019, 26 pages. [cited by applicant]
USPTO; Non-Final Office Action for U.S. Appl. No. 14/788,770 dated Mar. 5, 2019, 8 pages. [cited by applicant]
USPTO; Non-Final Office Action for U.S. Appl. No. 14/788,770 dated Sep. 10, 2015, 22 pages. [cited by applicant]
USPTO; Final Office Action for U.S. Appl. No. 14/788,770 dated Apr. 29, 2016, 9 pages. [cited by applicant]
USPTO; Non-Final Office Action for U.S. Appl. No. 15/243,908 dated Sep. 14, 2018, 27 pages. [cited by applicant]
USPTO; Final Office Action for U.S. Appl. No. 15/243,908 dated Apr. 2, 2019, 29 pages. [cited by applicant]
USPTO; Non-Final Office Action for U.S. Appl. No. 15/243,917 dated Oct. 5, 2018, 23 pages. [cited by applicant]
USPTO; Final Office Action for U.S. Appl. No. 15/243,917 dated Jun. 13, 2019 24 pages. [cited by applicant]
USPTO; Non-Final Office Action for U.S. Appl. No. 15/253,807 dated Oct. 30, 2018, 34 pages. [cited by applicant]
USPTO; Final Office Action for U.S. Appl. No. 15/253,807 dated Jul. 31, 2019, 33 pages. [cited by applicant]
USPTO; Non-Final Office Action for U.S. Appl. No. 15/253,818 dated Oct. 16, 2018, 28 pages. [cited by applicant]
USPTO; Non-Final Office Action for U.S. Appl. No. 16/665,862 dated Jun. 10, 2021, 8 pages. [cited by applicant]
USPTO; Non-Final Office Action for U.S. Appl. No. 17/676,562 dated Jan. 19, 2024, 10 pages. [cited by applicant]